**BACKGROUND**

- **Alopecia areata (AA):** An autoimmune disease with an underlying immunoinflammatory pathway characterized by a scarring hair loss.
- **Evidence:** The trial outcome measures were the absence of regrowth as determined by SALT ≤10 or SALT ≤20 responses among patients receiving ritlecitinib doses of ≥30 mg.

**OBJECTIVE**

- The post hoc analysis of ALLEGRO-2b/3 examined the associations between prior use of AA therapies and hair regrowth responses in patients receiving ritlecitinib for AA.

**METHODS**

**Study design and patients**

- **Key inclusion criteria in ALLEGRO-2b/3:**
  - Age ≥12 years with a diagnosis of AA with ≥50% scalp hair loss due to AA (including AT and AU)
  - No evidence of terminal hair regrowth within 6 months at both the screening and baseline visits

**Assessments and analysis**

- **Severity of Alopecia Tool (SALT) score ≥20 (≥50% scalp hair loss) and SALT score ≤10 at Weeks 24 and 48**
- **Patients were grouped by previous exposure to AA treatments:**
  - ILCS: Intralesional corticosteroids
  - Topical immunotherapy
  - Systemic immunosuppressants
- **Multiple logistic regression analyses evaluated the association between response to ritlecitinib (SALT ≤10 or SALT ≤20) and any prior use of AA treatment, adjusting for patient and clinical covariates at Weeks 24 and 48:**

**RESULTS**

- **OR of SALT ≤10 and any prior use of AA therapy among patients receiving ritlecitinib:***

**Table 1. Previous exposure to AA treatments**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n (%)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No prior treatment</td>
<td>45/256</td>
<td>1.0</td>
</tr>
<tr>
<td>Any prior treatment</td>
<td>40/134</td>
<td>1.47</td>
</tr>
</tbody>
</table>

**Figure 3. SALT score ≤10 response at Weeks 24 and 48 by prior exposure to AA therapies among patients receiving ritlecitinib ≥30 mg**

**Figure 4. Associations between prior use of AA therapies with SALT ≤20 response at Week 24 and Week 48**

**Figure 5. Associations between prior use of AA therapies with SALT ≤10 response at Week 24 and Week 48**

**Figure 6. Associations between prior use of any AA therapy with SALT ≤20 and SALT ≤10 response at Week 24 and Week 48**

**CONCLUSIONS**

- **Prior exposure to ILCS or systemic immunotherapy was associated with differences in the likelihood of SALT ≤10 or SALT ≤20 responses among patients receiving ritlecitinib doses of ≥30 mg.**
- **These results suggest that there is no effect on longer-term treatment response to ritlecitinib based on prior treatment history, highlighting the importance of maintaining ritlecitinib therapy to evaluate the full therapeutic response.**

---

**ABBREVIATIONS**

- AA, alopecia areata
- AT, alopecia totalis
- AU, alopecia universalis
- BMI, body mass index
- DNCB, dinitrochlorobenzene
- ILCS, intralesional corticosteroids
- SALT, Severity of Alopecia Tool
- TCI, topical calcineurin inhibitors
- TEC, tyrosine kinase expressed in dermatitis (KIN11)
- TCA, tricarboxylic acid cycle
- TCI, topical calcineurin inhibitors
- TEC, tyrosine kinase expressed in dermatitis (KIN11)
- TCA, tricarboxylic acid cycle

**ACKNOWLEDGMENTS**

- The authors thank the patients, site staff, and other contributors to this study, who made this work possible.
- The authors also thank the study investigators, site staff, and other contributors to this study, who made this work possible.
- The authors further thank the study investigators, site staff, and other contributors to this study, who made this work possible.

**REFERENCES**